Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.59 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.59 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.56 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.56 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.56 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | FBP1 | P09467 | 1/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12450407 | 0.89 | P2RY1 (0.68) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL12450421 | 0.88 | P2RY1 (0.52) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL12450414 | 0.83 | P2RY1 (0.72) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL12450397 | 0.83 | P2RY1 (0.77) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL3296163 | 0.78 | P2RY1 (0.79) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL3046222 | 0.78 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL5055892 | 0.78 | P2RY1 (0.92) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL1744586 | 0.76 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Diadenosine Tetraphosphate SCHEMBL10069136 | 0.76 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL6516963 | 0.76 | P2RY1 (1.00) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-08-15 | — | — | US | disclosed |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2019-01-03 | — | — | US | disclosed |
| US-9938573-B2 | Methods and kits for nucleic acid sequencing | QUANTUMDX GROUP LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170037463-A1 | METHODS AND KITS FOR NUCLEIC ACID SEQUENCING | QUANTUMDX GROUP LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-20170037463-A1 | METHODS AND KITS FOR NUCLEIC ACID SEQUENCING | QUANTUMDX GROUP LIMITED (GB) | 2017-02-09 | — | — | US | disclosed |
| US-9410196-B2 | Methods and kits for nucleic acid sequencing | QUANTUMDX GROUP LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-9410196-B2 | Methods and kits for nucleic acid sequencing | QUANTUMDX GROUP LIMITED (GB) | 2016-08-09 | — | — | US | disclosed |
| US-20160139133-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20160139133-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2016-05-19 | — | — | US | disclosed |
| US-20150259731-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150259731-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LTD (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20110165572-A1 | METHODS AND KITS FOR NUCLEIC ACID SEQUENCING | QUANTUMDX GROUP LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110165563-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110165563-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | QUANTUMDX GROUP LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110165572-A1 | METHODS AND KITS FOR NUCLEIC ACID SEQUENCING | QUANTUMDX GROUP LIMITED (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259731-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-11180523-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-20190004055-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-20190248827-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-10273261-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
| US-20110165563-A1 | DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS | POLM, RNGTT, TYMP | P2RY1 2147/4885P2RY2 2556/4885SRC 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.